Clinical trials: Mucositis Oral
Ebola Virus
Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)
Ebola virus has infected and killed people, mostly in Africa. In 2014, the Ebola virus has affected several thousand people. There is no approved effective way to treat or prevent Ebola.
- Trial name
- NCT02314923
- Testing
- V920 Vaccine
- Volunteers
- 513 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Malignant Solid Tumour
Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors
This is a three-part open label phase 1 study designed to determine the safety profile, MTD, PK and tumor and biomarker response after IT or IV administration of a single dose of VSV-IFNβ-NIS, or combined IT followed by IV…
- Trial name
- NCT02923466
- Testing
- VSV-IFNβ-NIS, VSV-IFNβ-NIS and avelumab
- Where
- 6 sites in United States
- Volunteers
- 76 people
- Sponsor
- Vyriad, Inc.
Mucositis
Phase 2a Study to Evaluate Suppression of 5-Fluorouracil -Induced Mucositis by TK112690
Patients expected to receive a 500 mg/m2 of Leucovorin by iv \& 500 mg/m2 of Fluorouracil (5FU) by iv bolus for their Colorectal Cancer.
- Trial name
- NCT05669521
- Testing
- TK-112690
- Where
- 5 sites in India
- Volunteers
- 24 people
- Sponsor
- Tosk, Inc.
Candidiasis, Oral
CelAgace™ OraRinse Solution for Treatment of Candidiasis
CelAgace™ OraRinse (silver citrate complex and acemannan) Solution is planned to be evaluated for safety and effectiveness as a potential treatment for candidiasis, a yeast infection, commonly known as thrush, which is associated…
- Trial name
- NCT03250923
- Testing
- silver citrate complex and acemannan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- CelaCare Technologies, Inc.
Melanoma, Head and Neck Squamous Cell Carcinoma
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts.
- Conditions
- Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer
- Trial name
- NCT04291105
- Testing
- VV1, Cemiplimab
- Where
- 13 sites in United States, Brazil
- Volunteers
- 87 people
- Sponsor
- Vyriad, Inc.
Oral Mucositis
RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the incidence of severe oral mucositis in patients with head and neck cancers.
- Trial name
- KEVLARx (NCT05966194)
- Testing
- RRx-001, Intensity Modulated Radiation Therapy (IMRT), Cisplatin for injection 100 mg/m2
- Where
- 14 sites in United States
- Volunteers
- 216 people
- Sponsor
- EpicentRx, Inc.
Oral Mucositis, Nausea
ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial
RATIONALE: Polymerized (cross-linked) sucralfate malate paste (ProThelial) may be an effective single therapy approach for the management of chemoradiation mucositis, treating and preventing its occurrence in the oral cavity…
- Conditions
- Oral Mucositis, Nausea, Vomiting, Diarrhea
- Trial name
- NCT02016807
- Testing
- ProThelial
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Ashley Downs Bioscience
Oral Mucositis
Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers
The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the duration or length of severe oral mucositis in patients with head and neck cancers.
- Trial name
- PREVLAR (NCT03515538)
- Testing
- RRx-001, Cisplatin for injection, Radiation Therapy
- Where
- 12 sites in United States
- Volunteers
- 53 people
- Sponsor
- EpicentRx, Inc.
Stomatitis
The Clinical Study for Evaluation of Efficacy and Safety of EGF on Oral Mucositis in Radiation Therapy Patients
The purpose of this Study is to evaluate the efficacy and safety of rhEGF on oral mucositis in patients receiving the radiation therapy or the concurrent chemo-radiotherapy
- Trial name
- NCT01099891
- Testing
- rhEGF
- Where
- 2 sites in South Korea
- Volunteers
- 300 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Oral Mucositis
A Trial Assessing Chemo Mouthpiece Device With Best Supportive Care for Symptoms of Chemotherapy-Induced Oral Mucositis
This study will compare the use of the Chemo MouthpieceTM device along with best supportive oral care to best supportive oral care alone to rate the effectiveness of Chemo MouthpieceTM in lessening symptoms associated with…
- Trial name
- NCT04595838
- Testing
- Chemo Mouthpiece, Best Supportive Care only
- Where
- 11 sites in United States
- Volunteers
- 176 people
- Sponsor
- Chemo Mouthpiece
Sore Throat, Aphthous Ulcer
Observational Study of OROSEDAL in Sore Throat and Minor Oral Lesions
This prospective, multicenter, national, observational, non-interventional post-market clinical follow-up study will evaluate the performance and safety of OROSEDAL in children and adults with sore throat or minor oral lesions…
- Conditions
- Sore Throat, Aphthous Ulcer, Oral Lichen Planus, Minor Mouth Lesion
- Trial name
- NCT07620353
- Testing
- OROSEDAL
- Where
- France
- Volunteers
- 124 people
- Sponsor
- Laboratoires Elerte
Mucositis, Solid Tumors
Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer
The purpose of this research study is to test the safety and effectiveness of palifermin to determine if weekly doses can be safely administered to reduce the incidence (occurrence of), duration (length of time) and severity…
- Conditions
- Mucositis, Solid Tumors, Stomatitis, Head and Neck Cancer
- Trial name
- NCT00101582
- Testing
- palifermin, cisplatin chemotherapy, Radiotherapy
- Volunteers
- 188 people
- Sponsor
- Swedish Orphan Biovitrum
Nipah Virus Infection
A Phase 1 Study to Evaluate Safety & Immunogenicity of RVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects
A Phase 1 Study to Evaluate the Safety and Immunogenicity of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects
- Trial name
- NCT05178901
- Testing
- PHV02
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Public Health Vaccines LLC
Stomatitis, Oral Mucositis
Efficacy of SNX-1012 in the Treatment of Oral Mucositis
Oral mucositis (OM) is a common and debilitating toxicity induced by many chemotherapy (CT) regimens and by radiation to the head and neck.
- Trial name
- NCT00385515
- Testing
- SNX-1012 (meclocycline sulfosalicylate)
- Where
- 27 sites in United States, India
- Volunteers
- 81 people
- Sponsor
- Mucosal Therapeutics
Hematologic Malignancies
Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation
The purpose of this study is to evaluate the efficacy of TXA127 to reduce the incidence (Grade II-IV) of acute Graft-vs.-Host Disease (aGVHD) in adult subjects undergoing double umbilical cord blood transplantation (UCBT).
- Trial name
- NCT01882374
- Testing
- TXA127
- Where
- United States
- Sponsor
- Tarix Pharmaceuticals
Oral Mucositis Due to Radiation, Radiation Dermatitis
Feasibility and Safety of CareMin650 in Patients at Risk of or Suffering From Oral Mucositis and/or Radiation Dermatitis
The main objective of the present study is to investigate the feasibility, safety and tolerability of CareMin650 in patients with 1) head \& neck cancer at high risk of or suffering from oral mucositis and/or radiation dermatitis…
- Trial name
- SafePBM (NCT03988556)
- Testing
- Photobiomodulation using CareMin650 at 6 Joules (curative intent), Photobiomodulation using CareMin650 at 3 Joules (prophylactic intent)
- Where
- 5 sites in France
- Volunteers
- 72 people
- Sponsor
- NeoMedLight
Sloughing Skin, Mucosal Inflammation
A Study to Assess the Impact of a Non-SLS Toothpaste Upon Oral Mucosal Desquamation
This study is to compare the effect on oral mucosal desquamation of a non-SLS toothpaste and an SLS-containing toothpaste..
- Trial name
- NCT03598881
- Testing
- Treatment
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Unilever R&D
Stomatitis
Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant
CG53135-05, a recombinant human fibroblast growth factor-20 (rhFGF-20) protein, is under investigation for the prevention of oral mucositis.
- Trial name
- NCT00104065
- Testing
- CG53135-05, velafermin
- Where
- 9 sites in United States
- Sponsor
- CuraGen Corporation
Oral Mucositis, Stomatitis
A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis
CG53135-05 (velafermin), a recombinant human fibroblast growth factor-20 (rhFGF-20) protein, is under investigation for the prevention of oral mucositis.
- Trial name
- NCT00323518
- Testing
- velafermin
- Where
- 33 sites in United States
- Volunteers
- 390 people
- Sponsor
- CuraGen Corporation
Oral Mucositis (Ulcerative), Oral Mucositis (Ulcerative) Due to Radiation
Photobiomodulation to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Head & Neck Cancer Patients
The overall purpose of this clinical study is to evaluate safety and efficacy of the MuReva Phototherapy System with a light delivery mouthpiece to reduce the severity of oral mucositis (OM) in adult patients with squamous cell…
- Conditions
- Oral Mucositis (Ulcerative), Oral Mucositis (Ulcerative) Due to Radiation, Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy, Head and Neck Cancer
- Trial name
- NCT03972527
- Testing
- Photobiomodulation, Routine Oral Care and Analgesia
- Where
- 12 sites in United States
- Volunteers
- 85 people
- Sponsor
- MuReva Phototherapy Inc.